Cardiac Issues With Noncardiac Surgery Joseph F. Winget, MD FACC Clinical Assistant Professor University of Vermont Medical School Champlain Valley Cardiovascular.

Slides:



Advertisements
Similar presentations
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Advertisements

Stenting Patients Needing Non-Cardiac Surgery
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines HEART FAILURE Working Group: Alan D. Bell, MD, CCFP; James D.
Cardiovascular Pre-Operative Evaluation for Non-Cardiac Surgery Jessica Thom PGY-1.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
What is Cardiology Clearance? Sheilah Bernard, MD, FACC Director, Cardiac Amb Services Sheilah Bernard, MD, FACC Director, Cardiac Amb Services 9:30-10:00am.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Cardioprotective Agents in the Total Joint Arthroplasty Patient: Are We Doing Enough? Eric Schwenk MD*, Kishor Gandhi MD MPH*, Javad Parvizi MD^, Eugene.
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
New guidelines for CABG
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Management of Stable Angina SIGN 96
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
Diagnosis, Management, & Follow-up Care Of CAD/AMI BARRY BERTOLET, MD CARDIOLOGY ASSOCIATES OF NORTH MS.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Contemporary Management of Myocardial Ischemia
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
An MI, a Stent, Bleeding, and Surgery! What Do I Do? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Evaluation of the Cardiac Patient Before Non-Cardiac Surgery
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Atrial Fibrillation Jay H. Lee, MD Denver Health Medical Center Wednesday 2 July 2008.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for the management of patients.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate.
Choosing Wisely: Cardiology Jeffrey Ziffra D.O. Mercy Medical Center – North Iowa 10/14/2016.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
The Primary and Secondary Prevention of Cardiovascular Disease
Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.
Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.
Anticoagulation after peripheral Vascular Intervention
Management of Patients on Chronic Oral Anticoagulant Therapy
Antithrombotic Therapy in Atrial Fibrillation
Polypharmacy Anticoagulation: AF meets PCI
Antithrombotic Therapy in Peripheral Artery Disease
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
Glenn N. Levine et al. JACC 2016;68:
ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization  Manesh R. Patel, MD, FACC, Steven.
Glenn N. Levine et al. JACC 2016;68:
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Peter K. Smith, MD  The Annals of Thoracic Surgery 
Glenn N. Levine et al. JACC 2011;58:e44-e122
Lee A. Fleisher et al. JACC 2014;64:e77-e137
Presentation transcript:

Cardiac Issues With Noncardiac Surgery Joseph F. Winget, MD FACC Clinical Assistant Professor University of Vermont Medical School Champlain Valley Cardiovascular Associates, P.C.

Objectives Preoperative risk assessment Anticoagulation and antithrombotic issues Postoperative Management Endocarditis prophylaxis

Disclosures None

Surgery or not? 87 year old white female with known critical AS fall and breaks her hip. No CHF, MI, syncope Stable and relatively independent before the fall. LVEF 65% 82 year old white male with known CAD. Stable angina pectoris. Catheterization shows occluded LAD which was fed by collaterals No CHF AODM and HTN Severe worsening spinal stenosis and weakness LVEF 50%

Preoperative cardiac issues How healthy is the patient? How active is the patient? How risky in the planned surgery? Is preoperative cardiac testing necessary? What preventive measures can be taken to reduce cardiac risk?

L’Italien JACC 1996;27:779

JACC 2002; 39:542

JACC :542

Is testing predictive of outcomes? Circ 1997; 95: 53

Cardiac event rates and dobutamine echocardiography JAMA 2001; 285:1865

Who to test? Intermediate risk patients undergoing intermediate or high risk surgery Testing does not add additional information in low risk or high risk patient groups.

What test? Well validated –Exercise or pharmacologic echocardiography –Exercise or pharmacologic Cardiolite Not well validated –CTA –MRI –Cardiac angiography*

Therapies to reduce perioperative cardiac complications Revascularization –Percutaneous revascularization –CABG Medical therapy

Benefit of CABG Circ 1997; 96: 1882

McFalls E et al. N Engl J Med 2004;351: Long-Term Survival among Patients Assigned to Undergo Coronary-Artery Revascularization or No Coronary-Artery Revascularization before Elective Major Vascular Surgery

McFalls E et al. N Engl J Med 2004;351: Long-Term Use of Medical Therapy in the Revascularization and No-Revascularization Groups at 24 Months after Randomization

Medical therapy to lower risk Lindenauer, PK JAMA May 5; 291(17)2092

Beta blocker use? NEJM 1996; 335:1713

Beta blocker use?

Recommendations Revascularization for appropriate clinical indications Maximize adjuvant medical therapy –Aspirin –Statin –Beta blocker Close perioperative follow-up –Prolonged telemetry monitoring

Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Fleisher, L. A. et al. J Am Coll Cardiol 2007;50:e159-e242 Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular disease, or cardiac risk factors for patients 50 years of age or greater

Surgery or not? 87 year old white female with known critical AS fall and breaks her hip. No CHF, MI, syncope Stable and relatively independent before the fall. 82 year old white male with known CAD. Stable angina pectoris Catheterization shows occluded LAD which was fed by collaterals No CHF AODM Severe worsening spinal stenosis and weakness

Cardiac Issues in noncardiac surgery Establish patient risk Assign procedural risk Test intermediate risk patients undergoing intermediate or high risk surgery Optimize medical therapy Revascularization when clinically indicated ACC/AHA Guidelines JACC 2007; 50:

Anticoagulation / Antiplatelet Agents 55 year old male s/p CABG in Drug eluting stent placed to native vessel in August of Needs colonoscopy Can plavix and aspirin be safely stopped? 70 year old white female with chronic AF needs shoulder surgery History of CVA Warfarin 5 mg daily Does the patient need some form of bridging preoperatively?

Anticoagulation / Antithrombotic Issues Anticoagulants – warfarin –Atrial fibrillation –Venous thrombosis –Prosthetic heart valves Antithrombotic agents – clopidogrel –Bare metal stents vs. drug eluting stents

Do you need to stop antiplatelet / anticoagulation therapy? Procedural risk for bleeding –Low risk for bleeding Athrocentesis Cataract surgery Dental cleaning / extraction Cutaneous surgery

CHADS score - AF Circulation 2004; 110:2287JAMA 2001; 285:2864

Atrial fibrillation Bridge –AF and prosthetic valves –AF and significant LV dysfunction (EF<40%) –AF and any prior thrombotic event (CVA, TIA, arterial emboli) –“high risk” patients No bridging –Low risk patients

How to bridge Stop warfarin for 48 hours Start lovenox at 1mg/kg SQ BID for 6 doses Stop lovenox the morning before surgery

Prosthetic heart valves Bioprosthetic valves –All, if in atrial fibrillation Mechanical valves –All, regardless of rhythm

Venous thrombosis Deep venous thrombosis Pulmonary emboli Hypercoagulable states –Factor V Leiden –Protein C / S deficiencies –Lupus anticoagulant

How to Bridge Stop warfarin Start replacement therapy once INR < 2.0 –IV heparin –SQ low molecular weight heparin - lovenox

Coronary stents

Recommendations – stent patients Bare Metal Stents –Delay elective procedures for at least 1 month and preferably 6 months –Restart clopidogrel as soon as possible –Loading dose? Drug eluting stents –Delay elective procedures for 1 year –Continue aspirin –Restart clopidogrel as soon possible –Loading dose?

Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Fleisher, L. A. et al. J Am Coll Cardiol 2007;50:e159-e242 Proposed approach to the management of patients with previous percutaneous coronary intervention (PCI) who require noncardiac surgery, based on expert opinion

Improved cardiac care for noncardiac surgery? Yes, we can!

Perioperative Medication Management Beta Blockerscontinue Alpha agonistscontinue Calcium blockerscontinue prn ACE / ARBstop preoperatively start when stable Statinscontinue Diureticsas needed

Endocarditis prophylaxis 70 year old female with rheumatic valvular heart disease and Bjork-Shiley MVR in 1984 needs dental work. Are antibiotics required?

SBE prophylaxis Antibiotics –All Prosthetic valves –Prior bacterial endocarditis –Cyanotic congenital heart disease (CHD) –Any repair CHD with prosthetic material * No Antibiotics –Uncomplicated valvular heart disease –Pacemakers or defibrillators –Hypertrophic cardiomyopathy Circ 2007; 115